← Lexicon·Mechanism Evidence Studies Conflict PK Routes Amounts Storage Safer Use Adverse Interactions Safety Authorities Legal Cofactors SourcesES ↗

Peptide entry · Research other

Teduglutid

Teduglutide · Gattex · Revestive

Highest evidence

Human RCT

Studies recorded

2· 2 in humans

Legal status · US

Prescription

Scientific context only. Not medical advice, not a recommendation to use.

At a glance

Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome.

Researched for

Short bowel syndromeIntestinal failureIntestinal mucosal growth

Official status

US: Prescription

FDA-approved (2012, Gattex) for short bowel syndrome; later also for children.

Jump to

Mechanism →Studies →Legal status →Risks & hygiene →

At a glance

2studies 2in humans 2countries 2adverse events

01 Mechanism
02 Evidence overview2
03 Study landscape2
05 Pharmacokinetics
★06d Safer use & risks
07 Adverse events2
07b Interactions
11 Legal status by country2
12 Reconstitution calculator
13 Related peptides
14 Study register2
15 Sources & methodology

Overview

What is it?

Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome.

How is it meant to work? →

Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at …

What do studies show? →

Human RCTReduces the need for parenteral nutrition/fluid in short bowel syndrome (STEPS trial: 63% vs. 30% response).

What do users report?

No documented community reports.

Mechanism of action

Evidence at a glance

Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.

2 observations · 2 tiers

Human RCT

Human trial

What the studies show

Human RCT

Mensch

Jeppesen PB, et al. 2012

Reduces the need for parenteral nutrition/fluid in short bowel syndrome (STEPS trial: 63% vs. 30% response).

What does NOT follow: Approved, narrowly defined indication; not transferable to general gut health.

Human trial

Mensch

Promotes growth of small-intestinal villi (trophic GLP-2 effect).

What does NOT follow: This trophic effect also underlies the need for intestinal/polyp monitoring.

Pharmacokinetics

No robust pharmacokinetic human data available. A model curve is not invented.

06d

Safer use & risks

Risk notes for harm reduction — descriptive, not a usage or dosing guide.

Important — please read

This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.

This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.

Online numbers are not a benchmark

Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.

Sterility & infection risk

Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.

Unknown product quality

Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.

Mind interactions

Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.

Warning signs — seek medical help

With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.

A doctor, not a forum

Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.

Known adverse events from studies

Factual reporting of what studies observed. Not a safety statement for individual use.

Human trial

Abdominal pain, nausea, injection-site reactions

Factual report from the trials.

häufig

Human trial

Intestinal polyp/neoplasia risk (monitoring mandated)

Because of the trophic growth stimulus, colonoscopies are mandated — a documented safety requirement, not a usage instruction.

Überwachungs-relevant

07b

Interactions & combinations

Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.

Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.

No documented interactions recorded

We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.

Legal status by country

Country	Status	Note	Checked
United States	Prescription	FDA-approved (2012, Gattex) for short bowel syndrome; later also for children.	2026-06
Germany	Prescription	Approved across the EU as Revestive, prescription-only.	2026-06

Reconstitution calculator

Pure mg/mL maths — works like a calculator. Not a usage recommendation.

Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?

1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.

Substance (mg)Printed on the label

Solvent (mL)Liquid you add

2.50

mg / mL

5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.

Study register

Human RCTRandomised controlled trial

Jeppesen PB, et al. · 2012

Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure (STEPS)

SampleAdults with parenteral-dependent short bowel syndrome.

EndpointProportion with 20–100% reduction in parenteral support at 24 weeks.

Concrete results

Response rate

63% vs 30%

vs Placebo · 24 Wochen

Findings:Clinically meaningful response in 63% on teduglutide vs. 30% on placebo.

Limitations:Rare disease, limited sample; the trophic effect requires long-term monitoring.

PubMed ↗

Human RCTRandomised controlled trial

Jeppesen PB, et al. · 2011

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome

Findings:Early randomized trial showing the benefit of teduglutide in reducing parenteral requirements.

PubMed ↗

Sources & method

Last reviewed

2026-06-11

Get new studies on Teduglutid

Science only, no sales. Unsubscribe anytime.

We store your email only for the newsletter. Unsubscribe anytime. Privacy

Country

Status

Note

Checked

United States

Prescription

FDA-approved (2012, Gattex) for short bowel syndrome; later also for children.

2026-06

Germany

Prescription

Approved across the EU as Revestive, prescription-only.

2026-06

Mechanism of action

Evidence at a glance

What the studies show

Pharmacokinetics

Safer use & risks

Known adverse events from studies

Interactions & combinations

Legal status by country

Reconstitution calculator

Related peptides

Study register

Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure (STEPS)

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome

Sources & method

Get new studies on Teduglutid

Mechanism of action

Evidence at a glance

What the studies show

Pharmacokinetics

Safer use & risks

Known adverse events from studies

Interactions & combinations

Legal status by country

Reconstitution calculator

Related peptides

Study register

Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure (STEPS)

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome

Sources & method

Get new studies on Teduglutid